NEW YORK (
CHANGE IN RATINGS
rated new Hold at ThinkEquity. $30 price target. Execution risk remains high, because of increased competition.
rated new Buy at ThinkEquity. $44 price target. Company has a growing commercial franchise and a deep pipeline.
downgraded at Oppenheimer to Perform from Outperform, Oppenheimer said. Low coverage ratio.
upgraded at Argus from Hold to Buy, Argus Research said. $75 price target. Stock appears oversold, following a 20% decline.
upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Healthcare reform should help hospitals expand margins.
downgraded at BofA/Merrill from Neutral to Underperform, Bank of America/Merrill Lynch said. $10 price target. Company has lost some top managers and growth is slowing in regional markets.
Enbridge Energy Partners
upgraded at Oppenheimer to Outperform from Perform, Oppenheimer said. $36 price target. Attractive growth outlook.
upgraded at Jefferies to Buy from Hold, Jefferies said. $38 price target. Risk-reward has improved.
upgraded at BofA/Merrill to Buy, Bank of America/Merrill Lynch said. $57 price target. Company is seeing higher prices and sales and using new summer initiatives.
(NKE - Get Report)
downgraded at Baird to Neutral. $85 price target. Stronger dollar and slower growth in China are hurting margins.
Nike downgraded at Sterne Agee to Neutral. Estimates also cut, given slower growth, especially in China.
Nike downgraded at DA Davidson to Neutral. $93 price target. Company faces growth headwinds and lowered guidance.
upgraded at JP Morgan from Neutral to Overweight, JP Morgan said. $12 price target. Company has mutli-year sales and margin growth drivers in place.
downgraded at Citigroup to Neutral from Buy, Citigroup said. $10 price target. Macro will be a headwind to margin expansion.
rated new Buy at Goldman. $73 price target. Company has multiple growth drivers, including the recent Vought acquisition.
upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Valuation call, relative to the group.